ÐÇ¿ÕÊÓÆµ

ÐÇ¿ÕÊÓÆµ response to ÐÇ¿ÕÊÓÆµ England Genomics Strategy

ÐÇ¿ÕÊÓÆµ England has today published its first , alongside a genetic testing service.Ìý

Our industry stands ready to work with ÐÇ¿ÕÊÓÆµ England and others to deliver this strategy and ensure as many people can access the latest cutting-edge diagnostics and medicines as soon as possible. Richard Torbett, Chief Executive, ÐÇ¿ÕÊÓÆµ

Commenting on today's publication, ÐÇ¿ÕÊÓÆµ Chief Executive Richard Torbett said:Ìý

“We are at the dawn of a medical revolution where our growing knowledge of genetics is poised to radically improve patient care and outcomes. To deliver on this promise, we need to get better at taking new scientific innovations from industry labs and into ÐÇ¿ÕÊÓÆµ clinics where they can start to benefit patients. This strategy is at the heart of making this happen.

“We are pleased to see the strategy’s focus on expanding genomic testing, upskilling the workforce, and supporting genomic research and the introduction of new technologies, which will be essential to supercharging patient access to the genomic medicine service and driving more cutting-edge scientific research.

“Our industry stands ready to work with ÐÇ¿ÕÊÓÆµ England and others to deliver this strategy and ensure as many people can access the latest cutting-edge diagnostics and medicines as soon as possible.â€

Ìý

The global genomics market has grown significantly over recent years and is estimated to grow by £10.75bn between 2021-2025. In the UK, genomics related activity has generated an estimated total turnover of £2.4bn over recent years. (1)

The ÐÇ¿ÕÊÓÆµ will continue to work with ÐÇ¿ÕÊÓÆµ England, the Office for Life Sciences (OLS) and others to ensure ÐÇ¿ÕÊÓÆµ patients can benefit from the latest advances in genomic medicine and that the UK is a globally attractive destination for genomic research and investment.

In early November, the ÐÇ¿ÕÊÓÆµ will publish its full report with additional recommendations on how to take this strategy further.

(1) From Ìý

TAGS
  • Genomics

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ÐÇ¿ÕÊÓÆµ exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the ÐÇ¿ÕÊÓÆµ so patients can get new treatments faster and the ÐÇ¿ÕÊÓÆµ can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.